Biotech financing in times of pandemic

20-Apr-2021 11:08

In 2020 German biotech companies managed to raise a record sum of more than 3 billion Euro in equity capital. What had the pandemic to do with this and will the corona-virus have a long-term positive impact on the financing of German biotechs? What are the industry expectations from the government? How has the German government addressed the challenges of COVID 19 on the German biotech and VC industry? What drives the IPO activity in the US and Europe in 2021 and are «COVID» stories distorting the picture?

Stefan Fischer, Managing Partner (Finance) of our Mainsponsor TVM Capital Life Science will discuss these and further questions with her panelists:

  • Matthias Kromayer, General Partner, MIG
  • Christian Stiebner, Investment Manager, KfW Capital
  • and Otello Stamapacchia, Managing Director, Omega Funds

The discussion will take place Thursday 28 April starting 1 pm.

We value your privacy

We and our partners store or access information on devices, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for the purposes described below. You may click to consent to our and our partners’ processing for such purposes. Alternatively, you may click to refuse to consent, or access more detailed information and change your preferences before consenting. Your preferences will apply to this website only. Please note that some processing of your personal data may not require your consent, but you have a right to object to such processing. You can change your preferences at any time by returning to this site or visit our privacy policy.